Page 1233 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1219

Immune response, 643 tacrolimus, 986 asthma treated with, 351
Immune system, 977–985 clinical uses of, 985t, 995–996 chronic obstructive pulmonary disease
abnormal immune responses in, autoimmune disorders, 996 treated with, 152
981–985 organ and bone marrow transplanta- Indinavir, 872t, 880–881
autoimmunity, 984 tion, 996 Indirect thrombin inhibitors, 612f,
hypersensitivity, 981–983, 983f cytotoxic agents 612–614. See also Heparin
immunodeficiency, 984–985 azathioprine, 988 Indomethacin, 648. See also Nonsteroidal
genetic variations on function of, 83–85 cyclophosphamide, 988 anti-inflammatory drugs
drug-induced hypersensitivity reac- hydroxychloroquine, 989 (NSAIDs)
tions, 83t, 83–85, 84f methotrexate, vincristine, and on eicosanoid synthesis, 332
IFNL3 (IL-28B), 77t, 80t, 85 cytarabine, 989 structure and properties of, 644f, 645t
normal immune responses in, 977–980 pentostatin, 989 Indoramin, 160
adaptive immune system, 979f, pyrimidine synthesis inhibitors, Inert binding sites, 7
979–980, 981f, 982f 988–989 Infantile spasms, 410, 431. See also Seizures
innate immune system, 977–979 vinblastine, 989 Infant pharmacology, 1050–1054
Immunization, 1175–1182. See also specific dimethyl fumarate, 989 Infertility drugs
vaccines fingolimod hydrochloride, 989–990 female, gonadotropin-releasing hormone,
active, 1175, 1176t–1178t glatiramer acetate, 989 677
passive, 1175, 1180t–1181t, 1181 glucocorticoids, 985t, 985–986 male
routine childhood, recommended immunosuppressive antibodies, 990–991 gonadotropin-releasing hormone, 677
schedule for, 1175, 1179t antilymphocyte and antithymocyte hCG and hMG, 675
for travelers, 1182 antibodies, 990 Inflammation, 977, 979f
untoward reactions to, legal liability for, chimeric molecules, 990 aspirin for, 336
1181–1182 development of, 990 chronic, 643
Immunodeficiency. See also specific hyperimmune immunoglobulins, 991 kinins in, 307
immunodeficiency immune globulin intravenous, NSAIDs for, 643
description of, 984–985 990–991 therapeutic strategies for, 643. See also
primary disorders of, immune globulin Rh 0 (D) immune globulin, 991 Analgesics
intravenous for, 1180t monoclonal antibodies, 991–995 Inflammatory bowel disease (IBD),
Immunoglobulins abciximab, 995 1106–1112, 1116t. See also
human, 1175, 1179 antitumor, 991–992 specific agents
hyperimmune, 991 delivering isotopics and toxins to aminosalicylates for, 1106–1109, 1107f,
Immunomodulators, therapeutic, 996, 998 tumors, 993 1116t
cytokines, 996, 997t, 998 denosumab, 995 anti-integrin therapy for, 1112
dermatologic eculizumab, 995 antitumor necrosis factor therapy for,
imiquimod, 1074 immunosuppressants and anti- 1110–1112, 1111t
tacrolimus and picrolimus, inflammatory agents, 993–995, glucocorticoids for, 1109, 1116t
1074–1075 994f methotrexate for, 1110, 1116t
Immunomodulatory derivatives of palivizumab, 995 purine analogs for, 1109–1110, 1116t
thalidomide (IMiDs), 988 pegatinib, 995 therapeutic pyramid for, 1106, 1107f
Immunopharmacology, 977–1001 ranibizumab, 995 Infliximab
immune system in, 977–985 raxibacumab, 995 inflammatory bowel disease treated with,
immunologic drug reactions and drug mycophenolate mofetil, 987 1110–1112, 1111t, 1116t
allergy, 998–1000 proliferation signal inhibitors, 986–987 psoriasis treated with, 1079
autoimmune (type II) drug reactions, thalidomide, 987–988 rheumatic disorders treated with, 654f,
982–983, 999 Implantable cardioverter-defibrillator 655
immediate (type I) drug allergy, 982, (ICD), 246b Influenza
983f, 998–1000 Inamrinone, 219, 225t drugs for, 891–892
serum sickness and vasculitis (type III) Incertohypothalamic pathway, 516 amantadine and rimantadine, 892
reactions, 999–1000 Incontinence, urinary, 124, 136 investigational, 892
types of, 998 Incretin mimetics oseltamivir and zanamivir, 891–892
immunomodulation therapy, 996–998 dipeptidyl peptidase-4 inhibitors, vaccines for
immunosuppressive therapy, 985–995 762–763, 769t Haemophilus influenzae type b
clinical uses of, 995–996 glucagon-like peptide-1 and, 762 conjugate (Hib), 1176t
preparations available, 1000t glucagon-like peptide-1 receptor inactivated, 1176t
Immunosuppressive therapy, 985–995 agonists, 762 live attenuated, 1177t
calcineurin inhibitors IND, 12f, 17 Ingenol mebutate, 1083–1084
cyclosporine, 986 Indacaterol Inhalants, ionotropic receptors in, 585